Comparison of Continuous Cardiac Rhythm Monitoring and Standard Care in Post-MI Patients With Significant Scar and Reduced LVEF (PRAETORIAN-LUX)

November 10, 2026 updated by: Reinoud. E. Knops, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Prospective Randomized Comparison of Standard Care Versus Continuous Cardiac Rhythm Monitoring of Patients With Significant Myocardial Scar and Moderately Reduced Ejection Fraction After Myocardial Infarction

After myocardial infarction (MI), reduced LVEF (≤35%) is a known risk marker for sudden cardiac death (SCD), yet many SCD cases occur with LVEF >35% as myocardial scarring remains a strong arrhythmogenic substrate regardless of preserved function. Non-sustained ventricular tachycardias ((NS)VTs) predict malignant arrhythmias and highlight the importance of early detection.

The primary objective is to determine whether continuous cardiac rhythm monitoring after myocardial infarction improves the detection of cardiac arrhythmias that require medical intervention by conducting a prospective, multi-center, international, randomized trial.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

After myocardial infarction (MI), reduced left ventricular ejection fraction (LVEF ≤35%) is a well-known risk factor for sudden cardiac death (SCD), but many SCD cases occur in patients with preserved or mildly reduced LVEF (>35%) due to the arrhythmogenic potential of myocardial scar tissue. Non-sustained ventricular tachycardia (NSVT) is an early marker of malignant arrhythmias, underscoring the value of continuous rhythm monitoring. This prospective, multicentre, randomized trial investigates whether continuous cardiac rhythm monitoring using an implantable loop recorder in post-MI patients with LVEF >35 ≤50% and proven myocardial scar improves detection of clinically relevant arrhythmias compared with standard care. Secondary aims include evaluating the incidence of NSVT/VT/VF, premature ventricular contraction (PVC) burden, and the prognostic value of biomarkers such as NT-proBNP, Lp(a), IL-6, and CRP, as well as assessing patient safety perception and the potential health benefits of early intervention.

Study Type

Interventional

Enrollment (Estimated)

256

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Reinoud E Knops, Professor, MD, PhD
  • Phone Number: +31205666555
  • Email: r.e.knops@amc.nl

Study Contact Backup

Study Locations

    • North Holland
      • Amsterdam, North Holland, Netherlands, 1105
        • Recruiting
        • Amsterdam Medical Center Amsterdam
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients ≥ 18 years of age with a recent (≤ 12 months) STEMI or NSTEMI according to the definition by current ESC/AHA guidelines

  • LVEF >35-≤50% measured > 48 hours after index STEMI or NSTEMI

    o In case a candidate has an LVEF <35% after a recent MI, the responsible physician can decide to treat the patient with GDMT first and reassess the LVEF after 3 months post-MI

  • Clinically relevant myocardial scar, identified by one of the following criteria:

    • Post-MI TTE: Akinetic or dyskinetic myocardial segments seen on two anatomically adjacent echocardiographic segments suggestive for ischemic scar
    • Post-MI ECG: Pathologic Q-waves of ≥0.04 seconds in duration and ≥25% of the R wave amplitude in at least two contiguous leads
    • Post-MI MRI: Late gadolinium enhancement (LGE) in a typical ischemic distribution pattern, characterized by subendocardial or transmural involvement in at least one myocardial segment corresponding to a coronary artery territory, and confirmed on two orthogonal imaging planes
    • Post-MI nuclear imaging: Severely reduced perfusion and absent of metabolic activity in two or more contiguous segments, with tracer uptake less than 50%

Exclusion Criteria:

  • Patients implanted with any CIED or with a guideline indication for a CIED
  • Indication for chronic renal dialysis
  • Patients with life expectancy shorter than 12 months due to any medical condition
  • NYHA Class IV
  • Participation in another trial that may interfere
  • Woman who are pregnant or breast feeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Implantable Cardiac Monitor arm

Patients undergoing an ICM implant for continuous cardiac monitoring

Implantable cardiac monitor implantation for continuous monitoring

No Intervention: Control group

Control group with standard of care without ICM implant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to first documented cardiac arrhythmia prompting medical intervention
Time Frame: Throughout the planned 36-month participant follow-up period.

Composite endpoint defined as the first documented cardiac arrhythmia that prompts a clinical action, including a change in medication, a diagnostic or interventional procedure, or hospitalization. Each participant contributes only their first qualifying event, regardless of arrhythmia type or clinical action. The outcome will be reported as the cumulative incidence of this composite event, expressed as a percentage, and compared between the insertable cardiac monitor (ICM) and standard-care groups using time-to-event analysis.

Throughout the planned 36-month participant follow-up period.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with non-sustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation
Time Frame: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented non-sustained ventricular tachycardia (NSVT), ventricular tachycardia (VT), or ventricular fibrillation (VF). A participant meets the endpoint upon documentation of any component and is counted once, even if multiple components or episodes occur. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from any cause
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants who die from any cause during follow-up, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from a cardiovascular cause
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants who die as a result of a cardiovascular complication, as defined in the protocol, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with a documented cardiac arrhythmia
Time Frame: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented cardiac arrhythmias as defined in the protocol. A participant is counted once upon documentation of any qualifying arrhythmia, regardless of the number or type of subsequent arrhythmias. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented bradycardia
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether bradycardia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented sinus node dysfunction
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented sinus node dysfunction. Each participant is counted once. Counts will be reported by study group and according to whether sinus node dysfunction prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrioventricular block
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrioventricular block, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether atrioventricular block prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrial fibrillation
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrial fibrillation meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether atrial fibrillation prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented supraventricular tachycardia other than atrial fibrillation
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented supraventricular tachycardia other than atrial fibrillation, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether the arrhythmia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented non-sustained ventricular tachycardia
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented non-sustained ventricular tachycardia (NSVT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether NSVT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular tachycardia
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular tachycardia (VT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular fibrillation
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular fibrillation (VF) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VF prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving invasive interventions for cardiac arrhythmias
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants receiving at least one invasive clinical intervention for a documented cardiac arrhythmia. Each participant is counted once, regardless of the number of invasive interventions received. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with supraventricular arrhythmias necessitating clinical intervention
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented supraventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with bradycardia necessitating clinical intervention
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with ventricular arrhythmias necessitating clinical intervention
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented ventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving an implantable cardioverter-defibrillator
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing implantable cardioverter-defibrillator (ICD) implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving a pacemaker
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing pacemaker implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving appropriate implantable cardioverter-defibrillator therapy
Time Frame: From ICD implantation through the end of the planned 36-month participant follow-up period.

Number of participants receiving at least one appropriate implantable cardioverter-defibrillator (ICD) therapy after ICD implantation. Each participant is counted once, regardless of the number of appropriate therapies received.

From ICD implantation through the end of the planned 36-month participant follow-up period.
Number of participants with complications related to insertable cardiac monitor implantation
Time Frame: From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.

Number of participants in the ICM group experiencing at least one complication related to ICM implantation, including implantation-site infection, hematoma, or device migration. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
Number of participants with suspected serious complications related to arrhythmia-directed clinical interventions
Time Frame: Throughout the planned 36-month participant follow-up period.

Number of participants experiencing at least one suspected serious complication related to a clinical intervention performed for a detected cardiac arrhythmia. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

Throughout the planned 36-month participant follow-up period.
Number of participants meeting the composite health-risk endpoint
Time Frame: Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.

Composite endpoint comprising an increase of at least one NYHA class, heart failure admission, cardiovascular death, percutaneous coronary intervention, myocardial infarction, cerebrovascular accident, coronary artery bypass grafting, or valve surgery. A participant meets the endpoint if any component occurs and is counted once, regardless of the number of components experienced. Counts will be compared between study groups.

Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
Percentage of participants with documented non-sustained ventricular tachycardia
Time Frame: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the insertable cardiac monitor (ICM) group with at least one adjudicated non-sustained ventricular tachycardia (NSVT) episode during each assessment window. Each participant is counted once per window, regardless of the number of episodes. The percentage is calculated as the number of participants with NSVT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of non-sustained ventricular tachycardia episodes per monitoring day
Time Frame: During the first 30 days and first 6 months after initiation of LUX monitoring.

Rate of all adjudicated non-sustained ventricular tachycardia (NSVT) episodes recorded by the insertable cardiac monitor (ICM). All qualifying episodes are counted, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of NSVT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. NSVT is classified according to the protocol definition.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Percentage of participants with documented sustained ventricular tachycardia
Time Frame: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the ICM group with at least one adjudicated sustained ventricular tachycardia (VT) episode during each assessment window. Each participant is counted once per window. The percentage is calculated as the number of participants with sustained VT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of documented sustained ventricular tachycardia episodes per monitoring day
Time Frame: During the first 30 days and first 6 months after initiation of LUX monitoring

Rate of all adjudicated sustained VT episodes recorded by the ICM, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of sustained VT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. Results are expressed as sustained VT episodes per monitoring day.

During the first 30 days and first 6 months after initiation of LUX monitoring
Percentage of participants meeting the early composite PVC, NSVT, VT, or VF endpoin
Time Frame: During the first 30 days and first 6 months of participant follow-up.

Percentage of participants meeting a composite endpoint comprising PVC, NSVT, sustained VT, or ventricular fibrillation (VF). A participant meets the endpoint if any component occurs and is counted once per assessment window. The percentage is calculated as the number of qualifying participants divided by the number in the analysis population, multiplied by 100, and compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Rate of events meeting the early composite PVC, NSVT, VT, or VF endpoint
Time Frame: During the first 30 days and first 6 months of participant follow-up.

Rate of events meeting the composite endpoint comprising PVC, NSVT, sustained VT, or VF. Qualifying events will be counted according to protocol description and divided by time of follow-up. Results will be compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Mean premature ventricular contraction burden
Time Frame: Throughout ICM monitoring, anticipated to last 36 months after implantation.

Mean premature ventricular contraction (PVC) burden recorded by the ICM in the ICM group. For each participant, daily device-recorded PVC burden, expressed as a percentage, will be averaged over the observation period. The participant-level averages will then be summarized as the group mean PVC burden

Throughout ICM monitoring, anticipated to last 36 months after implantation.
Change from baseline in EQ-5D-5L score
Time Frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Health status assessed using the EQ-5D-5L specific score. Changes from baseline will be calculated at 12, 24, and 36 months and compared between the ICM and standard-care groups to assess differences in change over time. There is also an visual analogue sclae with scores that ranges from 0 to 100, with higher scores indicating better perception of being healthy. Changes will be summarized using these scores

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from baseline in self-assessed NYHA class
Time Frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Functional status assessed using self-assessed New York Heart Association (NYHA) class. Changes from baseline will be determined at 12, 24, and 36 months and compared between the ICM and standard-care groups. Changes will be reported as NYHA class. Higher NYHA classes indicate greater functional limitation.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from the initial post-implant assessment in Florida Patient Acceptance Survey using the FPAS specific score
Time Frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Device acceptance assessed using the Florida Patient Acceptance Survey (FPAS) in the ICM group only. Changes from the initial post-implant assessment will be calculated at 12, 24, and 36 months to assess change over time. The score ranges from 0 to 100, with higher scores indicating better acceptance.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
NT-proBNP concentration
Time Frame: Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

NT-proBNP concentration measured in blood samples and expressed in ng/L. Baseline concentrations will be evaluated as a predictor of cardiac arrhythmias. Follow-up concentrations will be collected only when measured during routine clinical care.

Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean daily coffee intake assessed using the study questionnaire
Time Frame: At baseline, 12-, 24-, and 36 months

Participant-reported coffee intake assessed using the additional study questionnaire and expressed as cups per day. The mean number of cups consumed per day will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months
Mean weekly alcohol intake assessed using the study questionnaire
Time Frame: At baseline, 12-, 24-, and 36 months

Participant-reported alcohol intake assessed using the additional study questionnaire and expressed as standard drinks per week. Mean weekly intake will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Reinoud E Knops, Prof, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 17, 2026

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

April 1, 2031

Study Registration Dates

First Submitted

October 20, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NL-010971

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.